Barclays Increases Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $38.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price upped by Barclays from $35.00 to $38.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s target price indicates a potential upside of 12.74% from the stock’s current price.

Several other research analysts also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Jefferies Financial Group increased their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Sunday, January 18th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Finally, The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA traded up $0.64 during trading hours on Friday, hitting $33.71. The company had a trading volume of 4,023,629 shares, compared to its average volume of 10,411,535. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The firm has a market capitalization of $38.66 billion, a price-to-earnings ratio of 28.09, a PEG ratio of 1.89 and a beta of 0.66. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $33.64. The firm has a 50 day simple moving average of $30.29 and a 200 day simple moving average of $23.03.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 48.20%. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same period in the prior year, the firm posted $0.71 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the transaction, the insider directly owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. This trade represents a 80.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Roberto Mignone sold 77,400 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total value of $2,340,576.00. Following the sale, the director owned 367,600 shares of the company’s stock, valued at $11,116,224. This represents a 17.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 622,060 shares of company stock worth $17,076,965 over the last 90 days. Company insiders own 0.49% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently added to or reduced their stakes in TEVA. Mitsubishi UFJ Trust & Banking Corp grew its holdings in shares of Teva Pharmaceutical Industries by 2.4% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 470,043 shares of the company’s stock worth $14,670,000 after acquiring an additional 11,145 shares during the period. D.A. Davidson & CO. grew its stake in Teva Pharmaceutical Industries by 15.2% in the fourth quarter. D.A. Davidson & CO. now owns 104,920 shares of the company’s stock worth $3,275,000 after purchasing an additional 13,844 shares during the period. Concurrent Investment Advisors LLC purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $255,000. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its holdings in Teva Pharmaceutical Industries by 9.2% in the fourth quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 1,875,521 shares of the company’s stock worth $58,535,000 after purchasing an additional 158,790 shares in the last quarter. Finally, OLD National Bancorp IN purchased a new position in Teva Pharmaceutical Industries during the fourth quarter valued at $223,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.